Story perspectives

Novo Nordisk Upgraded: Analysts Split as Earnings Beat Estimates

9/18/2025

Summary

Story summary

Rothschild & Co upgraded Novo Nordisk A/S (NYSE:NVO) from neutral to buy on September 17, 2025, followed by Berenberg Bank's upgrade from hold to buy, resulting in a 1.7% price increase.
Analysts show mixed ratings: five buy, eleven hold, and one sell, with an average target price of $81.00.
Novo Nordisk reported quarterly earnings of $0.97 per share, surpassing estimates of $0.93, with revenue of $11.69 billion and a net margin of 35.60%.
Institutional investors own 11.54% of the stock, with recent stake increases from several firms.
The stock's market capitalization is around $259.86 billion, with a P/E ratio of 15.99.

History

Historical Context

The Euro was introduced by the European Union in 2000, marking a significant shift in global finance. Novo Nordisk, a leading Danish pharmaceutical company with a market capitalization of $259.86 billion, exemplifies the rise of multinational corporations in the EU. Institutional investors, holding 11.54% of its stock, play a crucial role in shaping market dynamics, particularly as Novo Nordisk reported earnings of $0.97 per share.

1 of 2

Story summary

Rothschild & Co upgraded Novo Nordisk A/S (NYSE:NVO) from neutral to buy on September 17, 2025, followed by Berenberg Bank's upgrade from hold to buy, resulting in a 1.7% price increase.
Analysts show mixed ratings: five buy, eleven hold, and one sell, with an average target price of $81.00.
Novo Nordisk reported quarterly earnings of $0.97 per share, surpassing estimates of $0.93, with revenue of $11.69 billion and a net margin of 35.60%.
Institutional investors own 11.54% of the stock, with recent stake increases from several firms.
The stock's market capitalization is around $259.86 billion, with a P/E ratio of 15.99.

1 / 2